PRRS Virus Vaccine Strains for Stable Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRRS vaccines are ineffective due to the high genetic mutation rate of the PRRS virus, leading to reduced protective immunity as the virus evolves, and they often revert to a virulent phenotype, causing significant economic losses in the swine industry.
Innovation Solution
Development of new PRRS virus strains such as G16X, 794A61, and 111698, which stimulate a strong interferon alpha response and do not inhibit interferon alpha production, providing enhanced immune protection without the need for serial passaging or attenuation, thereby reducing the risk of virulence reversion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modified live virus vaccines are used to protect swine from PRRS, then immune protection is provided, but the virus may revert to virulent phenotype causing disease
Solution Approach 1:
The patent uses site-directed mutagenesis to introduce specific amino acid substitutions in the GP5 glycoprotein of the PRRS virus. These parameter changes at the molecular level create a stable attenuated phenotype that prevents reversion to virulence while maintaining protective immunity. The specific mutations in GP5 alter viral properties to ensure safety without compromising immunogenicity.
2Reliability
If serial passaging is performed to attenuate the virus, then virulence is reduced, but the process is time-consuming and complex
Solution Approach 1:
The patent performs preliminary attenuation through controlled serial passaging in MARC-145 cells before final vaccine production. This preliminary action reduces virulence in advance, allowing the subsequent vaccine development process to proceed more efficiently with reduced risk. The pre-attenuated virus is then used as the basis for further genetic modification and vaccine formulation.
Solution Approach 2:
The patent replaces the traditional mechanical serial passaging method with molecular biology techniques, specifically site-directed mutagenesis. Instead of relying on repeated cultural passage to achieve attenuation, the invention directly introduces specific genetic mutations to create the desired attenuated phenotype, significantly reducing the time and complexity of the attenuation process.
3Object-affected harmful factors
If the vaccine strain is highly attenuated, then safety is improved, but protective efficacy may be reduced
Solution Approach 1:
The patent applies local quality changes by introducing specific mutations only in the GP5 glycoprotein region of the PRRS virus, rather than globally attenuating the entire virus. This localized approach allows the virus to maintain its immunogenic properties and protective efficacy while being attenuated in specific regions that control virulence. The GP5 mutations provide safety without compromising the overall protective immunity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These new strains induce a robust immune response, offering superior protection against heterologous PRRS virus challenges, reducing viremia, and maintaining a negligible virulence level, thus minimizing economic losses and health impacts on swine.
Implementation Method 1
stimulate a strong interferon alpha response and do not inhibit interferon alpha production
Data Source
AI summary
Provided herein are embodiments relating to porcine reproductive and respiratory syndrome (PRRS) virus, compositions comprising the virus, and methods of using the virus. The virus may be used to immunize a mammal, including swine. Methods for generating an immune response against PRRS virus in swine by administering a composition comprising the virus are provided.